Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.57 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14012798 | 0.85 | CHRNB2 (0.49) | CHRNB2CHRNA4KCNA5CHRNA7RIPK1 | |
| SCHEMBL7996307 | 0.84 | CHRNB2 (0.64) | CHRNB2CHRNA4CHRNA7RIPK1TDP1 | |
| SCHEMBL12197592 | 0.84 | CHRNB2 (0.72) | CHRNB2CHRNA4CHRNA7RIPK1TDP1 | |
| SCHEMBL10509238 | 0.84 | CHRNB2 (0.72) | CHRNB2CHRNA4CHRNA7RIPK1TDP1 | |
| SCHEMBL615299 | 0.80 | TSHR (0.56) | — | |
| SCHEMBL14350222 | 0.78 | CHRNB2 (0.50) | CHRNB2CHRNA4KCNA5CHRNA7RIPK1 | |
| SCHEMBL13970334 | 0.78 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNA7NR1D1SMN1; SMN2 | |
| SCHEMBL10243109 | 0.77 | CHRNB2 (0.48) | CHRNB2CHRNA4RIPK1TRPM8SMN1; SMN2 | |
| SCHEMBL4196487 | 0.77 | HRH1 (0.56) | CHRNB2CHRNA4KCNA5CHRNA7TDP1 | |
| SCHEMBL16606314 | 0.76 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNA7RIPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | SB PHARMCO PUERTO RICO INC. AND NEUROCRINE BIOSCIENCES, INC., A CORPORATION | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | CRHR1, CRHR2, CRH | CHRNB2 383/4885CHRNA4 298/4885KCNA5 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.